ASCO 2020: Combination therapy well-tolerated and highly effective for patients with IDH1-mutated AML
A combination therapy of ivosenidib (IVO) plus venetoclax (VEN) with or without azacitidine (AZA) was…
Browsing: ivosenidib
A combination therapy of ivosenidib (IVO) plus venetoclax (VEN) with or without azacitidine (AZA) was…